SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 20, 2001
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
VIRGINIA 0-30739 54-1972729
- -----------------------------------------------------------------------------------
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation) Identification No.)
800 East Leigh Street, Richmond, VA 23219
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (804) 828-6893
ITEM 5. OTHER EVENTS
On March 20, 2001, Insmed Incorporated issued a press release
announcing the results following a full analysis of its previously
reported Phase II trial of SomatoKine(R) in patients with Type 2
diabetes. A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference. The press release was
also posted on Insmed's website on March 20, 2001.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibit
99.1 Press Release dated March 20, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INSMED INCORPORATED
Date: March 21, 2001 By: /s/ Michael D. Baer
-------------------------------
Michael D. Baer
Chief Financial Officer
INSMED INCORPORATED
INDEX TO EXHIBITS
Exhibit Number
99.1 Press Release dated March 20, 2001.